01:49 PM EDT, 06/06/2024 (MT Newswires) -- Arbutus Biopharma ( ABUS ) said Thursday data from a phase 2a trial in patients with chronic hepatitis B virus infection showed that treatment with imdusiran followed by Barinthus Biotherapeutics' ( BRNS ) VTP-300 was generally safe and well-tolerated.

Based on preliminary end-of-treatment data, Arbutus said that the therapy resulted in maintenance of lower hepatitis B surface antigen levels during the post-treatment follow-up period.

The company said there were no serious adverse events, grade 3 or 4 adverse events or discontinuations due to treatment with imdusiran and VTP-300. The data were presented at the European Association for the Study of the Liver Congress.

Arbutus shares fell about 8% while Barinthus was up around 2% in recent trading.

Price: 3.35, Change: -0.29, Percent Change: -7.85